Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis

Summary

This is an investigational new drug clinical trial for combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using intravenous injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients. All subjects are monitored for safety (adverse events/severe adverse events) and evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration.

Timeline

Start

2023-12

Primary completion

2024-12

Completion

2026-12

Drugs

Indications